- Home
- UNCY vs CNTX Comparison
UNCY vs CNTX Comparison
Compare UNCY & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- CNTX
- Stock Information
- Founded
- UNCY 2016
- CNTX 2015
- Country
- UNCY United States
- CNTX United States
- Employees
- UNCY N/A
- CNTX N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- CNTX Health Care
- Exchange
- UNCY Nasdaq
- CNTX Nasdaq
- Market Cap
- UNCY 71.8M
- CNTX 60.7M
- IPO Year
- UNCY 2021
- CNTX 2021
- Fundamental
- Price
- UNCY $0.64
- CNTX $0.94
- Analyst Decision
- UNCY Strong Buy
- CNTX Strong Buy
- Analyst Count
- UNCY 3
- CNTX 6
- Target Price
- UNCY $5.50
- CNTX $6.50
- AVG Volume (30 Days)
- UNCY 1.1M
- CNTX 279.0K
- Earning Date
- UNCY 05-12-2025
- CNTX 05-07-2025
- Dividend Yield
- UNCY N/A
- CNTX N/A
- EPS Growth
- UNCY N/A
- CNTX N/A
- EPS
- UNCY N/A
- CNTX N/A
- Revenue
- UNCY N/A
- CNTX N/A
- Revenue This Year
- UNCY N/A
- CNTX N/A
- Revenue Next Year
- UNCY $1,677.16
- CNTX N/A
- P/E Ratio
- UNCY N/A
- CNTX N/A
- Revenue Growth
- UNCY N/A
- CNTX N/A
- 52 Week Low
- UNCY $0.20
- CNTX $0.55
- 52 Week High
- UNCY $1.29
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- UNCY 59.78
- CNTX 60.39
- Support Level
- UNCY $0.63
- CNTX $0.84
- Resistance Level
- UNCY $0.67
- CNTX $1.04
- Average True Range (ATR)
- UNCY 0.04
- CNTX 0.09
- MACD
- UNCY 0.01
- CNTX 0.03
- Stochastic Oscillator
- UNCY 86.36
- CNTX 78.95
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.